Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...
▎药明康德内容团队编辑阿斯利康(AstraZeneca)今日宣布其重磅PD-L1抑制剂Imfinzi(durvalumab)已获得美国FDA的批准,用于治疗接受铂类同步放化疗(cCRT)后病情未进展的局限期小细胞肺癌(LS-SCLC)成人患者。小细胞 ...
British drug maker AstraZeneca Plc (AZN.L, AZN) announced Thursday that the U.S. Food and Drug Administration has approved Imfinzi ...
AstraZeneca AZN announced that the FDA has approved its blockbuster cancer drug Imfinzi (durvalumab) for treating ...
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to ...
Imfinzi (durvalumab) for adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed ...
Imfinzi has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer, LS-SCLC ...
Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.